Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Lantern Pharma's Starlight Therapeutics Receives FDA Clearance Its IND For Phase Ib/2a Glioblastoma Multiforme Trial

Author: Benzinga Newsdesk | August 06, 2025 07:32am

Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression
GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally
Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM

Posted In: LTRN